Hanwha Offers Up to $1.2 Billion for Austal US Business 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
US Judge Dismisses Gautam Adani Criminal Charges 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Airbus Joins Air India A320 Altitude Drop Probe 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
ADNOC Gas Targets Up to $4B Profit in 2026 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
